Skip to main content

Table 7 Limitations of treatment success in first-line ER+, HER2- mBC patients - overall by analysis of categories – from physician survey (n = 103)

From: Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States

  Not at all substantial Not at all substantial Moderately substantial Substantial Very substantial
  n % n % n % n % n %
Efficacy 7 6.8% 12 11.7% 25 24.3% 25 24.3% 34 33.0%
Safety/Tolerability 5 4.9% 22 21.4% 27 26.2% 35 34.0% 14 13.6%
Adherence 16 15.5% 29 28.2% 22 21.4% 27 26.2% 9 8.7%
Financial cost of treatments 2 1.9% 27 26.2% 30 29.1% 35 34.0% 9 8.7%
  1. mBC metastatic breast cancer